Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Vivek Patel, Katherine Baker, Danielle Fishman, Spencer Lessans, Trent Morris, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka M. Sengsayadeth, Shakthi Bhaskar

Blood (2023) 142 (Supplement 1): 5080.

https://doi.org/10.1182/blood-2023-189084

Published: 2023

Journal Articles

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Reem Alasbali, Mohsen Alzahrani, Saud Alhayli, Walid Rasheed, Phavina Akhom, Karina Wilkerson, Mohammed Essa, Riad Elfakih, Bader Alahmari, Hadeel Samarkandi, Syed Osman Ahmed, Ayman Saad, Hazza A. Alzahrani, Fahad Almohareb, Mahmoud Aljurf, Adetola A. Kassim, Ali D Alahmari

Blood (2023) 142 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2023-189914

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Shakthi Bhaskar, Katherine Baker, Danielle Fishman, Spencer Lessans, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka Sengsayadeth, Vivek Patel

Blood (2023) 142 (Supplement 1): 6940.

https://doi.org/10.1182/blood-2023-186217

Published: 2023

Journal Articles

Real-World Utilization of Daratumumab-Containing Induction Regimen in Transplant Eligible Newly Diagnosed Multiple Myeloma and Its Role in Patients Historically Excluded from Clinical Trials: A Single Institution Experience

Eden Ayele Biltibo, Adetola A. Kassim

Blood (2023) 142 (Supplement 1): 6709.

https://doi.org/10.1182/blood-2023-191244

Published: 2023

Journal Articles

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial

Shehu U. Abdullahi, Surayya Sunusi, Mohammed Sani Abba, Saifuddeen Sani, Hauwau Aminu Inuwa, Safiya Gambo, Awwal Gambo, Bilya Musa, Brittany V. Covert Greene, Adetola A. Kassim, Mark Rodeghier, Nafiu Hussaini, Mariana Ciobanu, Muktar H. Aliyu, Lori C. Jordan, Michael R. DeBaun

Blood (2023) 141 (8): 825–834.

https://doi.org/10.1182/blood.2022016620

Published: 2023

Includes: Supplemental data

Journal Articles

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 10462–10464.

https://doi.org/10.1182/blood-2022-170552

Published: 2022

Journal Articles

Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia

Rachel M Gilmore, Karin M Abernathy, Kendall C Shultes, Dwight D Eplin, Lindsay Orton, Adetola A. Kassim, Bipin N. Savani, Salyka M. Sengsayadeth, Brian G. Engelhardt, Wichai Chinratanalab, Tae Kon Kim, Bhagirathbhai Dholaria, Reena Jayani, Leena Choi, Elizabeth McNeer, Katie S. Gatwood

Blood (2022) 140 (Supplement 1): 2386–2388.

https://doi.org/10.1182/blood-2022-163283

Published: 2022

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 2383–2385.

https://doi.org/10.1182/blood-2022-165229

Published: 2022

Journal Articles

Insulin Secretion and β-Cell Function Are Preserved in Patients with Treated Hematological Malignancies

Rahul Shah, J. Matthew Luther, Michael Byrne, Dae Kwang Jung, Salyka M. Sengsayadeth, Bhagirathbhai Dholaria, Adetola A. Kassim, Bipin N. Savani, Wichai Chinratanalab, Reena Jayani, Brian G. Engelhardt

Blood (2022) 140 (Supplement 1): 6088–6089.

https://doi.org/10.1182/blood-2022-163409

Published: 2022

Journal Articles

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jennifer Marvin-Peek, Ashwin Kishtagari, Reena Jayani, Bhagirathbhai Dholaria, Tae Kon Kim, Emily F Mason, Brian G. Engelhardt, Heidi Chen, Adetola A. Kassim, Michael R. Savona, Bipin Savani, Michael Byrne

Blood (2022) 140 (Supplement 1): 11638–11640.

https://doi.org/10.1182/blood-2022-164631

Published: 2022

Journal Articles

Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide

Eden Biltibo, Reena Jayani, Leena Karnik, Adam Gassas, Farah O'Boyle, Daniel Dexter, Karina Wilkerson, Katie S. Gatwood, Lindsay Orton, Bhagirathbhai Dholaria, Bipin N. Savani, Brian G. Engelhardt, Salyka M. Sengsayadeth, Carrie Lynn Kitko, James P Connelly, Adetola A. Kassim, Josu de la Fuente

Blood (2022) 140 (Supplement 1): 7613–7615.

https://doi.org/10.1182/blood-2022-162825

Published: 2022

Journal Articles

Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis

Mesire Aydin, Elisabeth Dovern, Mariska M.G. Leeflang, Josu de la Fuente, Adetola A. Kassim, Bart J. Biemond, Erfan Nur

Blood (2021) 138 (Supplement 1): 424.

https://doi.org/10.1182/blood-2021-147809

Published: 2021

Journal Articles

In Africa, a High Proportion of Adults with HbSC Meet American Society of Hematology's Eligibility Criteria for Severe Sickle Cell Disease and Starting Hydroxyurea Therapy in a Clinical Trial Setting

William Kwesi Ghunney, Eugenia Vicky Asare, John Ayete-Nyampong, Yvonne Adomakoh, Adetola A. Kassim, Samuel A Oppong, Mark Rodeghier, Michael R. DeBaun, Edeghonghon Olayemi

Blood (2021) 138 (Supplement 1): 487.

https://doi.org/10.1182/blood-2021-153064

Published: 2021

Journal Articles

Cerebral Blood Flow, Brain Volume, and Age Predicts Executive Function in Sickle Cell Anemia

Kemar V. Prussien, Bruce E. Compas, Rachel Siciliano, R. Sky Jones, Abagail E. Ciriegio, Chelsea A. Lee, Adetola A. Kassim, Michael R. DeBaun, Manus Joseph Donahue, Lori C. Jordan

Blood (2021) 138 (Supplement 1): 976.

https://doi.org/10.1182/blood-2021-152504

Published: 2021

Journal Articles

Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Shehu Umar Abdullahi, MBBS, Binta W. Jibir, MBBS, Halima Bello-Manga, MBBS, MPH, FMCPath, Safiya Gambo, MBBS, FWACP, Hauwa Inuwa, MBBS, Aliyu Gaya Tijjani, MBBS, Aisha Amal Galadanci, MBBS, Awwal Musa Borodo, MBBS, FMCPath, Najibah Aliyu Galadanci, MBBS,MPH, Nura Idris, MBBS, FWACS, Abulkadir M Tabari, MBBS, FMCR, FICS, Lawal Haliru, MBBS, Khadija Bulama, BNSc, Gloria Bahago, RN, Mohammed A. Sani, B. Pharm, MSc, Aisha Suleiman, MBBS, Murtala Umar, B. Pharm, Charity Dooshima, Agba, B. Pharm, Aisha Kazaure, B. Pharm, Bilya Sani Musa, BSc, MPPA, MHE, Fahad M Usman, BSc, Abdulrasheed Sani, MIM, Awwal Gambo, PGDM, MD, Jamila S. Ibrahim, MBBS, MScPH, PMCPead, Mustapha Hikima, MBBS, FWACP, Aisha B. Musa, MBBS, Abdu H. Dambatta, MBBS, FWACP, Jamil Aliyu Galadanci, BSc, MSc, Brittany Covert Greene, MPH, CCRP, Djamila Labib Ghafuri, MPH, Mark Rodeghier, PhD, James Slaughter, PhD, Fenella Jane Kirkham, MD, Kathleen Neville, MD MS, FAAP, FCCP, Adetola A. Kassim, MDMS, Muktar Aliyu, MBBS, DrPH, MPH, Lori C. Jordan, MD PhD, Edwin Trevathan, MD MPH, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141436

Published: 2020

Journal Articles

Low- Versus Moderate-Dose Hydroxyurea for Secondary Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa: Final Results of a Randomized Controlled Trial, Sprint Trial

Shehu Umar Abdullahi, MBBS, Surayya M. Sunusi, Mohammed Sani Abba, Saifuddeen Sani, Aisha Galadanci, MBBS, Hauwa Inuwa, MBBS, Binta W. Jibir, MBBS, Brittany Covert Greene, MPH, CCRP, Adetola A. Kassim, MDMS, Lori C. Jordan, MD PhD, Muktar Aliyu, MBBS, DrPH, MPH, Mark Rodeghier, PhD, Awwal Musa Borodo, MBBS, FMCPath, Bilya Sani Musa, BSc, MPPA, MHE, Habu Abdu, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142896

Published: 2020

Journal Articles

Decreased Hospitalizations and Improved Health-Related Outcomes Using Client-Centered Therapy in Adults with Sickle Cell Disease with High Health Care Utilization

Jasmine McGhee, Karina L Wilkerson, NP, MSN, Deva Sharma, MD MS, Gina Frieden, PhD, Adetola A. Kassim, MDMS

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-143278

Published: 2020

NARROW

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Real-World Utilization of Daratumumab-Containing Induction Regimen in Transplant Eligible Newly Diagnosed Multiple Myeloma and Its Role in Patients Historically Excluded from Clinical Trials: A Single Institution Experience

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Insulin Secretion and β-Cell Function Are Preserved in Patients with Treated Hematological Malignancies

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide

Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis

In Africa, a High Proportion of Adults with HbSC Meet American Society of Hematology's Eligibility Criteria for Severe Sickle Cell Disease and Starting Hydroxyurea Therapy in a Clinical Trial Setting

Cerebral Blood Flow, Brain Volume, and Age Predicts Executive Function in Sickle Cell Anemia

Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Low- Versus Moderate-Dose Hydroxyurea for Secondary Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa: Final Results of a Randomized Controlled Trial, Sprint Trial

Decreased Hospitalizations and Improved Health-Related Outcomes Using Client-Centered Therapy in Adults with Sickle Cell Disease with High Health Care Utilization

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only